Lilly Drug Yields Positive Results

Posted: Updated:
The companies presented the results today in Switzerland. The companies presented the results today in Switzerland.
INDIANAPOLIS -

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Incyte Corp. (Nasdaq: INCY) say a treatment for patients with a certain type of dermatitis showed positive results in a Phase 2 study. Last month, the companies also announced plans to resubmit baricitinib to the U.S. Food and Drug Administration for the treatment of rheumatoid arthritis.

In April, the FDA rejected the New Drug Application for baricitinib as a once-daily treatment for rheumatoid arthritis, saying it needed more clinical results. The European Union approved the treatment in February.

The most recent study showed the drug, in combination with another treatment, "significantly improved" the signs and symptoms of moderate-to-severe atopic dermatitis. The trial involved 16 weeks of treatment, with 61 percent of patients receiving the treatment achieving a 50 percent or greater reduction in the overall severity of the condition.

The companies presented the results today at the European Academy of Dermatology and Venereology Annual Meeting in Switzerland.

  • Perspectives

    • The Power of Partnerships

      You can't go it alone in tech. All technology companies, regardless of their segment, live in an ecosystem comprised of organisms of varying complexity. More mature companies in established categories can function at the top of the food chain, consuming smaller companies through acquisition, but startups are seldom if ever in a position to gain dominance through acquisition. It’s vital for the success of a startup to be able to play well with others...

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Liberty Mutual Plans 400 New Carmel Jobs

      Boston-based Liberty Mutual Group Inc. is planning to add up to 400 Carmel jobs as part of a $14 million expansion plan. The insurance company has a global presence and currently employs 1,430 in central Indiana. The Indiana Economic Development Corp. says the new jobs, expected to be created by 2021, will pay more than the state and Hamilton County average wages. Plans call for Liberty Mutual to lease...

    • Vincennes Woman Sentenced For Tax Fraud

      U.S. District Judge Richard Young has sentenced a Vincennes woman to four years in prison on tax fraud charges. U.S. Attorney Josh Minkler's office says Deborah Richards pleaded guilty to preparing more than 350 false tax returns between 2014 and 2017. 

    • Soybean Alliance Chair Appointed to National Board

      The chairman of the Indiana Soybean Alliance Board of Directors has been named to a national board. Tom Griffiths of Kendallville is one of 19 new members appointed to the United Soybean Board by U.S. Secretary of Agriculture Sonny Perdue. 

    • Opioid Withdrawal Treatment Lands FDA Clearance

      The U.S. Food and Drug Administration has given clearance for a medical device developed in Indiana to help treat symptoms of opioid withdrawal. The device, known as the NSS-2 BRIDGE, was created by Innovative Health Solutions Inc. in Versailles.

    • FedEx Plans to Pump $170M Into Indy Hub

      FedEx Corp. (NYSE: FDX) is planning a $170 million investment in its hub at Indianapolis International Airport. In a tax abatement request introduced Monday evening to the City-County Council in Indianapolis, the company says plans call for more than two dozen additional full-time and nearly 180 part-time positions. FedEx says the installation of new package-handling equipment would also help retain some 730 full-timers and 3,200 part-timers.